Plaque Psoriasis
Conditions
Brief summary
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.
Interventions
Tapinarof cream, 1% applied topically once daily
Sponsors
Organon and Co
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open-label, single arm study
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male and female subjects age 18 to 75 with a confirmed clinical diagnosis of plaque psoriasis and stable disease for at least 6 months prior to the study * BSA involvement ≥ 20% * PGA score of ≥ 3 at screening * Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study * Capable of giving written informed consent
Exclusion criteria
* Psoriasis other than plaque variant * Any sign of infection of any of the psoriatic lesions * Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular (CV) system abnormalities or laboratory abnormality that will affect the health of the subject or interfere with the interpretation of the results * Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 4 weeks prior to the Baseline visit and/or plans to have such exposures during the study which could potentially impact the subject's psoriasis * Use of any prohibited medication within the indicated period before the first dose of study drug * Pregnant females or lactating females * The subject has received an investigational product within 30 days, 5 half-lives, or twice the duration of the biological effect of the study drug (whichever is longer) prior to first dose of study drug * Current or a history of cancer within 5 years except for fully excised skin basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix * Previous known participation in a clinical study with tapinarof
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Tmax and t1/2 | Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing) | The tmax is a pharmacokinetic parameter that describes the time point at which the highest concentration of the drug is achieved after dosing. |
| Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) | Baseline to Week 4 | Frequency and severity of AEs (local and systemic) |
| Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs | Baseline to Week 4 or Follow-Up (7-10 days after Week 4 Visit) | Changes in laboratory values, biomarker values, ECG results and vital signs were assessed for clinical relevance. |
| Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Day 1, Day 15, Day 29 | At each specified study visit, the Investigator (or qualified evaluator) assessed the presence and overall degree of irritation at the application sites, according to the LTS. The score will ideally represent an 'average' across all application sites. To the fullest extent possible, the same Investigator (or designated evaluator) will perform all tolerability assessments for an individual participant throughout the study. |
| Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: AUCo-tau | Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing) | The AUC in plasma is a pharmacokinetic parameter that describes the overall exposure of the drug. |
| Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Cmax | Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing) | The Cmax is a pharmacokinetic parameter that describes the highest concentration of the drug that is achieved after dosing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29) | Baseline and Day 1 | Identify clinically relevant effect of tapinarof on cardiac conduction |
| Analysis of the Relationship Between Plasma Concentration and ΔQTcF | Day 1 | The relationship between tapinarof plasma concentrations and ∆QTcF was investigated using a linear mixed-effects modeling approach with ΔQTcF as the dependent variable. A linear model with an intercept was fitted for tapinarof plasma concentrations, which represented the data in an acceptable way. The slope of tapinarof plasma concentration in the concentration-QTc relationship was estimated. |
| Mean Change From Baseline to Day 29 in Physician's Global Assessment (PGA) | Baseline to Day 29 | The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, scaling, and plaque thickness/elevation as guidelines. Higher PGA scores represent more severe disease. This scale ranges from 0 to 5, with 0 = best outcome. |
| Mean Change From Baseline to Day 29 Psoriasis Area and Severity Index (PASI) | Baseline to Day 29 | The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. |
| Mean Change From Baseline to Day 29 in Percent of Total Body Surface Area (%BSA) Affected | Baseline to Day 29 | The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Tapinarof (DMVT-505) Cream, 1% Tapinarof (DMVT-505) cream, 1% applied topically once daily
Tapinarof cream, 1%: Tapinarof cream, 1% applied topically once daily | 21 |
| Total | 21 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 1 |
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Age, Continuous | 51.8 years STANDARD_DEVIATION 13.91 |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 16 Participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 21 |
| other Total, other adverse events | 12 / 21 |
| serious Total, serious adverse events | 1 / 21 |
Outcome results
Primary
Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs)
Frequency and severity of AEs (local and systemic)
Time frame: Baseline to Week 4
Population: Safety Analysis Set: All randomized subjects who receive at least 1 application of study drug will be included in the safety analysis set.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) | Experienced an AE | 12 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) | Experienced a Treatment-Related AE | 6 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) | Experienced a Grade 3 (severe) AE | 2 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) | Experienced a Grade 4 (life-threatening) AE | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) | Experienced a Grade 5 (fatal) AE | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) | Experienced an SAE | 1 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) | Experienced a Treatment-related SAE | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) | Experienced TEAE leading to discontinuation from study/drug | 0 Participants |
Primary
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs
Changes in laboratory values, biomarker values, ECG results and vital signs were assessed for clinical relevance.
Time frame: Baseline to Week 4 or Follow-Up (7-10 days after Week 4 Visit)
Population: Safety Analysis Set: All randomized subjects who receive at least 1 application of study drug will be included in the safety analysis set.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs | Clinically Meaningful changes in hematology. | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs | Clinically meaningful changes in chemistry | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs | Clinically meaningful changes in urinalysis | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs | Clinically meaningful changes in tryptase | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs | Clinically meaningful changes in ECG parameters | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs | Clinically meaningful changes in vital signs | 0 Participants |
Primary
Number of Participants With Irritation as Assessed by the Local Tolerability Scale
At each specified study visit, the Investigator (or qualified evaluator) assessed the presence and overall degree of irritation at the application sites, according to the LTS. The score will ideally represent an 'average' across all application sites. To the fullest extent possible, the same Investigator (or designated evaluator) will perform all tolerability assessments for an individual participant throughout the study.
Time frame: Day 1, Day 15, Day 29
Population: Safety Analysis Set: All randomized subjects who receive at least 1 application of study drug will be included in the safety analysis set.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Baseline | No Irritation | 14 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Baseline | Mild | 5 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Baseline | Moderate | 1 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Baseline | Severe | 1 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Baseline | Very Severe | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Day 15 | No Irritation | 14 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Day 15 | Mild | 5 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Day 15 | Moderate | 1 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Day 15 | Severe | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Day 15 | Very Severe | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Day 29 | No Irritation | 17 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Day 29 | Mild | 2 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Day 29 | Moderate | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Day 29 | Severe | 0 Participants |
| Tapinarof (DMVT-505) Cream, 1% | Number of Participants With Irritation as Assessed by the Local Tolerability Scale | Day 29 | Very Severe | 0 Participants |
Primary
Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: AUCo-tau
The AUC in plasma is a pharmacokinetic parameter that describes the overall exposure of the drug.
Time frame: Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing)
Population: PK Analysis set: All subjects who have at least 1 application of study drug and have at least 1 evaluable PK assay result will be included in the PK analysis set. The majority of subjects had plasma levels of tapinarof and tapinarof sulfate that were below the level of quantitation (BQL). AUCo-tau value could not be calculated for 17 of the 21 subjects on Day 1 and 18 of the 19 subjects on Day 29, due to BQL samples. The metabolite (tapinarof sulfate) was BQL in all samples.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tapinarof (DMVT-505) Cream, 1% | Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: AUCo-tau | Day 1: tapinarof | 8037.29 pg*h/ml | Standard Error 6204.935 |
| Tapinarof (DMVT-505) Cream, 1% | Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: AUCo-tau | Day 29: tapinarof | 1985.54 pg*h/ml | — |
Primary
Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Cmax
The Cmax is a pharmacokinetic parameter that describes the highest concentration of the drug that is achieved after dosing.
Time frame: Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing)
Population: PK Analysis Set: All subjects who have at least 1 application of study drug and have at least 1 evaluable PK assay result will be included in the PK analysis set. No subject had measurable concentrations of the metabolite (tapinarof sulfate) at any time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tapinarof (DMVT-505) Cream, 1% | Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Cmax | Day 1: tapinarof Cmax | 898.33 pg/mL | Standard Deviation 1448.084 |
| Tapinarof (DMVT-505) Cream, 1% | Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Cmax | Day 29: tapinarof Cmax | 116.09 pg/mL | Standard Deviation 148.424 |
Primary
Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Tmax and t1/2
The tmax is a pharmacokinetic parameter that describes the time point at which the highest concentration of the drug is achieved after dosing.
Time frame: Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing)
Population: PK Analysis Set: All subjects who have at least 1 application of study drug and have at least 1 evaluable PK assay result were included in the PK analysis set. No subject had measurable concentrations of the metabolite (tapinarof sulfate) at any time point. An elimination half-life (t½) could not be determined in the majority of subjects (19/21 subjects \[90.5%\]) on Day 1 and all subjects on Day 29 due to the lack of detectable tapinarof in plasma samples in the elimination phase.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tapinarof (DMVT-505) Cream, 1% | Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Tmax and t1/2 | Day 1: tmax | 4.39 hours | Standard Deviation 5.476 |
| Tapinarof (DMVT-505) Cream, 1% | Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Tmax and t1/2 | Day 29: tmax | 4.02 hours | Standard Deviation 3.005 |
| Tapinarof (DMVT-505) Cream, 1% | Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Tmax and t1/2 | Day 1: t1/2 | 6.41 hours | Standard Deviation 0.691 |
Secondary
Analysis of the Relationship Between Plasma Concentration and ΔQTcF
The relationship between tapinarof plasma concentrations and ∆QTcF was investigated using a linear mixed-effects modeling approach with ΔQTcF as the dependent variable. A linear model with an intercept was fitted for tapinarof plasma concentrations, which represented the data in an acceptable way. The slope of tapinarof plasma concentration in the concentration-QTc relationship was estimated.
Time frame: Day 1
Population: PK/QTc Analysis Set included all subjects with at least 1 pair of post-dose PK and QTcF data from the same time point.~Of the 21 total subjects, there were 10, 8, 12, 10, 11, 11, 13, and 17 subjects with tapinarof plasma concentrations BLQ at the 1, 2, 3, 4, 5, 8, 12, and 24 hour post-dose time points, respectively. The number of participants with measurable tapinarof ranged from 4 to 13 across all the timepoints. The slope is determined based on the data available for each timepoint.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tapinarof (DMVT-505) Cream, 1% | Analysis of the Relationship Between Plasma Concentration and ΔQTcF | -0.00016 ms per pg/ml |
Secondary
Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29)
Identify clinically relevant effect of tapinarof on cardiac conduction
Time frame: Baseline and Day 1
Population: QT/QTc analysis set: The QT/QTc analysis set will include all subjects in the safety analysis set with measurements at Baseline as well as on-treatment with at least 1 post-dose time point with a valid ΔQTcF value.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tapinarof (DMVT-505) Cream, 1% | Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29) | Day 1 1 h Post-dose | -7.2 ms | Standard Error 1.79 |
| Tapinarof (DMVT-505) Cream, 1% | Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29) | Day 1 2 h Post-dose | -1.1 ms | Standard Error 2.92 |
| Tapinarof (DMVT-505) Cream, 1% | Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29) | Day 1 3 h Post-dose | -4.3 ms | Standard Error 1.88 |
| Tapinarof (DMVT-505) Cream, 1% | Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29) | Day 1 4 h Post-dose | -2.3 ms | Standard Error 3.04 |
| Tapinarof (DMVT-505) Cream, 1% | Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29) | Day 1 5 h Post-dose | -4.9 ms | Standard Error 2.87 |
| Tapinarof (DMVT-505) Cream, 1% | Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29) | Day 1 8 h Post-dose | -3.0 ms | Standard Error 2.6 |
| Tapinarof (DMVT-505) Cream, 1% | Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29) | Day 1 12 h Post-dose | -1.6 ms | Standard Error 2.18 |
| Tapinarof (DMVT-505) Cream, 1% | Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29) | Day 1 24 h Post-dose | -3.4 ms | Standard Error 1.97 |
Secondary
Mean Change From Baseline to Day 29 in Percent of Total Body Surface Area (%BSA) Affected
The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.
Time frame: Baseline to Day 29
Population: Safety Analysis Set: All randomized subjects who receive at least 1 application of study drug will be included in the safety analysis set.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tapinarof (DMVT-505) Cream, 1% | Mean Change From Baseline to Day 29 in Percent of Total Body Surface Area (%BSA) Affected | -14.44 percentage of BSA affected |
Secondary
Mean Change From Baseline to Day 29 in Physician's Global Assessment (PGA)
The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, scaling, and plaque thickness/elevation as guidelines. Higher PGA scores represent more severe disease. This scale ranges from 0 to 5, with 0 = best outcome.
Time frame: Baseline to Day 29
Population: Safety Analysis Set: All randomized subjects who receive at least 1 application of study drug will be included in the safety analysis set.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tapinarof (DMVT-505) Cream, 1% | Mean Change From Baseline to Day 29 in Physician's Global Assessment (PGA) | -1.2 score on a scale | Standard Deviation 1.03 |
Secondary
Mean Change From Baseline to Day 29 Psoriasis Area and Severity Index (PASI)
The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores.
Time frame: Baseline to Day 29
Population: Safety Analysis Set: All randomized subjects who receive at least 1 application of study drug will be included in the safety analysis set.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tapinarof (DMVT-505) Cream, 1% | Mean Change From Baseline to Day 29 Psoriasis Area and Severity Index (PASI) | -15.14 score on a scale |